SCHEMBL14723246

SCHEMBL14723246

O=C(O)NCc1cc2c(cc1F)ncn2C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
HPGD P15428 3/20 0.35
CYP1A2 P05177 1/20 0.35
IDO1 P14902 4/20 0.35
ALDH1A1 P00352 4/20 0.35
LMNA P02545 1/20 0.35
CYP2C19 P33261 1/20 0.34
YTHDC1 Q96MU7 1/20 0.34
CYP2C9 P11712 1/20 0.34
KCNH2 Q12809 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723427 0.82 HTR2C (0.37) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL14723485 0.81 YTHDC1 (0.42) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL14722645 0.81 CYP2C19 (0.39) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL15208540 0.81 RXRA (0.45) NPC1RAB9ASMN1; SMN2HSD17B10GAA
SCHEMBL14723071 0.79 NPC1 (0.44) NPC1RAB9ASMN1; SMN2HSD17B10GAA
SCHEMBL15216611 0.79 CYP2C19 (0.41) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL15209972 0.78 NPC1 (0.43) NPC1RAB9ASMN1; SMN2HSD17B10GAA
SCHEMBL14723034 0.78 YTHDC1 (0.42) NPC1RAB9ASMN1; SMN2HSD17B10RXRA
SCHEMBL14723472 0.77 CYP2C19 (0.39) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL14723247 0.77 IDO1 (0.38) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 CYP4F2 4881/4885CYP4A11 4771/4885NPC1 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.